ArticleCancer management and research2026
Haploidentical Allogeneic Cell Transplantation in Relapsed/Refractory Multiple Myeloma.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Although emerging therapies for multiple myeloma (MM) have improved treatment options, long-term disease control in relapsed/refractory (r/r) MM remains a challenge. While the effect of natural killer cell alloreactivity in haploidentical allogeneic hematopoietic cell transplantation (HCT) with post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GvHD) prophylaxis is considered a standard treatment option for several hematologic neoplasms, its use in MM is controversial. In this retrospective analysis, we evaluated a small cohort of consecutive patients with MM who underwent haploidentical allogeneic HCT with PTCy. Patients and Methods: With a median follow-up of 68 months (range, 2-109 months), seven consecutive patients with r/r MM underwent haploidentical HCT. All were heavily pre-treated, having received proteasome inhibitors, anti-CD38 antibody, immunomodulatory drugs, and at least one autologous HCT. Three patients received a chemotherapy-based reduced-intensity conditioning regimen combined with radioimmunotherapy. GvHD prophylaxis in all patients consisted of PTCy in combination with tacrolimus and mycophenolate mofetil. Results: All patients showed stable engraftment with complete donor chimerism. Haploidentical HCT resulted in initial response in all patients, with four patients achieving a complete remission (CR) and three a very good remission (VGPR) at first disease assessment post- HCT. All individuals surviving beyond day +100 experienced disease relapse or progression. Among the six surviving patients median time to relapse was 26.5 months (range, 5-81 months). At last follow-up, four of five surviving patients maintained a CR, while one patient remained in a very good partial remission, all following subsequent individualized therapies. Acute GvHD grades III-IV were observed in two patients, while four developed mild-to-moderate chronic GvHD, with no GvHD-related deaths at the last follow-up. Conclusion: In this small, selected cohort, haploidentical allogeneic HCT with individualized pre-treatment and conditioning regimens was associated with disease control in heavily pretreated patients with r/r MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.